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order to better understand the pathogenesis of UTI and
renal scarring.
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Pharmacologic intervention to
prevent hemodialysis vascular
access thrombosis: The next
generation of treatment?
To the Editor: We would like to extend our congrat-
ulations to Dr. Masaki et al [1] for their excellent work.
Their delivery system offers great promise for evalua-
tion of drugs for the local use of antineoplastic drugs,
like paclitaxel in the prevention of intimal hyperpla-
sia in hemodialysis vascular accesses. We would like to
note, however, that there are many more classes of drugs
that might be beneficial other than strictly antiprolif-
erative drugs [2]. Drugs that improve endothelial func-
tion, antimigratory agents, as well as those that affect the
glycocalyx formation should be studied. Even among an-
tiproliferative drugs, we found that systemic adminis-
tration of non-antineoplastic antiproliferative drugs like
angiotensin-converting enzyme (ACE) inhibiters seemed
to be of most benefit in grafts (as Dr. Masaki notes),
while antineoplastic antiproliferative agents such as pa-
clitaxel seemed of most benefit in endogenous fistulas [3].
A more recent multicenter study [4] confirmed the bene-
ficial properties of ACE inhibiters. Certainly, if antineo-
plastic agents are proven to be the most beneficial agents
for survival in all vascular accesses, then a local delivery
system such as described by Dr. Masaki would be a great
advance; however, there is such potential myocardial ben-
efit to the systemic use of ACE inhibiters in patients with
ischemic heart disease or cardiomyopathies that systemic
administration may prove simpler, more beneficial, and
cost effective. Nevertheless, we see Dr. Masaki’s work as
a great advance, and we applaud their continued efforts.
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Locking hemodialysis
catheters with cefotaxime
instead of gentamicin to avoid
potential ototoxicity
To the Editor: McIntyre et al compared gentamicin
(5 mg/mL) and heparin-locked, tunneled hemodialysis
catheter group with that of catheter-restricted filling of
standard heparin (5000 IU/mL) alone; gentamicin-locked
group recorded significantly lower catheter-related
bloodstream infections catheter-related bloodstream
infections (CRBSI) episodes compared with heparin
group (0.3/1000 vs. 4/1000 catheter days, P = 0.02) [1].
Dogra et al observed significantly lower incidence of
CRBSI (0.03 vs. 0.42 per 100 catheter days, P = 0.003),
and considerably higher mean infection-free catheter sur-
vival in the gentamicin group (catheter-restricted filling
of gentamicin/citrate, 40 mg/mL, and 3.13% citrate) com-
pared with heparin group (282 days vs. 181 days, P =
0.002). However, authors cautioned to establish the safety
of ‘locked’ dose of gentamicin for ototoxicity before the
technique was adopted because predialysis plasma gen-
tamicin levels were significantly higher in patients ran-
domized to gentamicin group compared with heparin
group (2.8 mg/L vs. <0.2 mg/L, P = 0.008) [2].
In view of recently reported ototoxicity [3, 4] regardless
of reasonably lower amount of aminoglycosides being
used for ‘locking’ catheters, a prospective case-controlled
study was carried out at our center using cefotaxime
(10 mg/mL) in combination with heparin (5000 U/mL) to
examine the lock’s efficacy in the prevention of CRBSI
[5]. Cefotaxime was chosen because of its broad antimi-
crobial spectrum and lack of ototoxic potentials. The
‘lock’ was applied two/three times a week postdialy-
sis. A significant relative-risk reduction in the incidence
of HD-tunneled catheter thromboses (1.340–4.701, P =
0.003), CRBSI-incidence (3.086–6.430, P < 0.0001), and
CRBSI-related mortality (1.517–5.864, P < 0.001) was
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Table 1. The outcome of locking tunneled hemodialysis catheters with cefotaxime and heparin in terms of ceatheter thrombosis, CRBSI
incidence, and CRBSI-related mortality (July 2002–June 2003)
Control group (N = 19) Study group (N = 67)
Tunneled HD (heparin alone, 6935 (cefotaxime + heparin, 24,455 Relative-risk reduction (%),
catheter events catheter days) N, total, % catheter days)a N, total, % 95% CI, P value
Catheter thromboses 6/19 (31.5) 9/67 (13.4) 57.3%, 1.340-4.701, 0.003
CRBSI episodes 17/19 (2.45/1000 catheter-days) 14/67 (0.57/1000 catheter-days) 76.7%, 3.086-6.430, < 0.0001
CRBSI-related mortality 5/19 (31.6) 7/67 (10.4) 67.1%, 1.517-5.864, < 0.001
95% CI, 95% confidence interval; CRBSI, catheter-related blood-stream infections.
aCefotaxime-heparin ‘lock’ solution composition, cefotaxime 10 mg/mL, heparin 5000 U/mL (to fill 1.3 mL in venous and 1.2 mL in arterial lumen of the catheter
with combined volume of approximately 2.5 mL containing total of 25 mg of cefotaxime).
observed in ‘locked’ group compared with control group
(Table 1).
Thus, locking HD catheters with cefotaxime may
evenly reduce the risk of development of CRBSI besides
minimizing the odds of aminoglycoside-associated oto-
toxicity.
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The differential impact of risk
factors on mortality in
hemodialysis and peritoneal
dialysis
To the Editor: In the article by Vonesh et al [1], dis-
crepancies in survival on different treatment modalities
for different patient groups is described in a large cohort
of patients. Although a considerable number of comor-
bidity conditions were included for this variable, I feel
that a major variable (i.e., the failed transplant recipi-
ent returning to dialysis) should have been included, or
preferably should have been added as a separate risk fac-
tor for mortality in dialysis patients.
These patients are at high risk for premature death,
excluding death within the first 90 days after starting
dialysis, especially when they continue even low dose im-
munosuppressive medication during dialysis [2, 3]. Fur-
thermore, these patients generally start on hemodialysis
during the first period after transplant failure (i.e., the first
year after graft failure). This would negatively influence
the outcome for this treatment modality as compared to
peritoneal dialysis with regard to mortality, and would,
therefore, be another plausible explanation for the high
initial mortality associated with hemodialysis found in
this study.
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Prevention of renal cell
carcinoma from hemodialysis
patients by regulating
epigenetic factors
To the Editor: Long duration of patients on hemodialy-
sis induces an increased incidence of renal cell carcinoma
